NUS Enterprise

Mesenchymal Stem Cell (MSC) Osteoprogenitors for Regenerative Medicine (Ref: 13140)

Technology #13140

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Dr. Zhiyong Poon
Managed By
Mr Tristan Rouille (
Files and Attachments
Tech Offer 13240 [PDF]

Mesenchymal stem cell (MSC) osteoprogenitors for regenerative medicine

(Ref: 13140)

Executive summary

  • A new isolated and previously unknown MSC subpopulation that delivers superior tissue repair capabilities.
  • Potential for more potent “off-the-shelf” MSC therapeutics.
  • Imminent launch of a phase I/II clinical trial at Singapore General Hospital: “Biophysically-Derived Pro-Angiogeneic Mesenchymal Stromal Cells (MSCs) for the Enhancement of Hematopoietic Recovery after Umbilical Cord Blood Transplantation.”
  • Ongoing pre-clinical evaluation of the use of the sub-population of MSCs in intervertebral disc repair.

Technology overview

During production of mesenchymal stromal cells (“MSC”) for human use, in vitro culture typically produces a heterogeneous population of cells which have different biological properties such that the therapeutic outcomes can be vastly different.

The Inventors have identified a sub-population of highly osteogenic MSCs in expanded cultures that exhibit superior tissue repair/regenerative potential for applications in hematopoiesis and orthopedics. The enhanced tissue repair/regenerative potential is believed to be due to these cell’s ability to secrete increased amounts of regenerative factors, such as IL-6, IL-8, VEGFA, etc.

A label-free means for isolation of these osteoprogenitor subpopulation has also been devised to facilitate translational efforts.

Main advantages

  • Deliver consistent MSC subpopulation with enhanced regenerative potential
  • Increase patient to patient reproducibility
  • Enhance MSC therapies for regenerative medicines and hematology/orthopedic market
  • Strong IP asset covering the method of producing the MSC subpopulation and its applications

Preclinical data


  • Technology has been incorporated into a GMP production process for production of a useful MSC subpopulation to treat cord blood transplant patients.
  • Phase I/II trials using this MSC subpopulation to boost blood cell recovery is underway (see above for preclinical data on how different MSC subpopulations support blood cell recovery).

Main inventor:  Dr. Zhiyong Poon.

Intellectual Property Status:

PCT US2015/000029 filed on February 18, 2015 as “Mesenchymal Stem Cell (MSC) Osteoprogenitors for Applications in Bone Marrow Regeneration and Hematopoietic Stem Cell (HSC) Transplants “.

National phases pending in SG, US, EP.


For more information, contact:

NUS Industry Liaison Office

  : + 65 6516 7175